CJC-1295 + Ipamorelin: Research on Growth Hormone Secretagogues
Share
The combination of a GHRH analog and a ghrelin-mimetic secretagogue peptide forms one of the most studied pairings in somatotropic axis research. CJC-1295 (without DAC) and Ipamorelin are frequently combined in experimental protocols aimed at exploring pulsatile growth hormone release.
Overview
CJC-1295 (without DAC) is a short-acting GHRH (growth hormone-releasing hormone) analog, while Ipamorelin is a selective growth hormone secretagogue peptide belonging to the GHRP family. Used together, they are studied for their complementary action on two distinct receptors of the somatotropic axis.
Proposed mechanism of action
CJC-1295 stimulates the GHRH receptor, while Ipamorelin acts on the ghrelin receptor (GHS-R), noted in several research models for its selectivity and lack of significant effect on cortisol or prolactin. This dual activation is studied for its potential to amplify the natural pulsatility of GH secretion without rapid receptor desensitization.
Scientific research focus
- Growth hormone secretion pulsatility
- Downstream IGF-1 signaling
- Research models on tissue and muscle recovery
- Studies on sleep architecture linked to the GH axis
Purity & quality standards
CELLOVATE applies strict internal standards to ensure consistency and reliability:
- High-purity peptide structure (≥99% HPLC)
- Independent third-party verification, batch by batch
- Batch-to-batch consistency
- Lyophilized form, nitrogen-sealed for stability
Storage & handling
This blend is supplied in lyophilized form. Once reconstituted, it should be stored between 2 and 8°C and used within the timeframe indicated on the supplied certificate of analysis.
Research use only
CJC-1295 + Ipamorelin is offered strictly as a research reagent for in-vitro and laboratory studies conducted by qualified professionals. It is not a drug, supplement, or cosmetic, and is not intended for human or animal use.
